head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing
ISSN: 1312-773X (Online)
Issue: 2017, vol. 23, issue 4
Subject Area: Medicine
DOI: 10.5272/jimab.2017234.1834
Published online: 18 December 2017

Original article

J of IMAB 2017 Oct-Dec;23(4):1834-1838
Zhivka Stoykova1, 2ORCID logo Corresponding Autoremail, Liliya Ivanova1, 2ORCID logo, Valentin Ikonomov3ORCID logo, Iliana Teodorova3, TatinaTodorova4ORCID logo,
1) Department of Microbiology and Virology, Medical Faculty, Medical University of Varna, Bulgaria,
2) Laboratory of Virology, University Hospital St. Marina, Varna, Bulgaria,
3) Clinic of Nephrology, University Hospital St. Marina, Varna, Bulgaria,
4) Department of Preclinical and Clinical Sciences, Faculty of Pharmacy, Medical University of Varna, Bulgaria.

Human cytomegalovirus is a ubiquitous herpesvirus that establishes lifelong latency after primary infection, but can cause life-threatening disease in immunosuppressed patients. CMV invasive disease leads to significant morbidity and mortality following kidney transplantation.
We tested 2 groups of patients - Group A included 20 potential kidney recipients and 29 potential donors investigated by ELISA and Group B included 53 adult kidney transplant recipients all of them tested in ELISA and 24 of them tested in QRT-PCR for CMV-DNA from plasma samples.
In group A 16 (80%) of 20 potential kidney recipients were anti-CMV IgG positive and 4 (20%) were anti-CMV IgG negative. Twenty eight of 29 potential donors were found seropositive, and only one was not infected.
In group B overall 119 ELISA tests for specific anti-CMV antibodies were performed. Anti-CMV IgM negative was 68 (57%) of the tested samples, twelve (10%) showed anti-CMV IgM equivocal results and 39 samples (33%) were with anti-CMV IgM positive. Seven of them (13,2%) showed repeatedly anti CMV IgM positive results. All 119 (100%) displayed аnti-CMV IgG positive results.
Overall 41 PCR analyses from plasma samples of 24 kidney transplant recipients (group B) were performed. CMV-DNA replication was detected in 5 plasma samples obtained from 3 patients (12.5%) at a different time - from 20 days till almost 8 years after the transplantation.
Despite the high seroprevalence to CMV 20% of the potential recipients were at high risk of primary infection when receiving a kidney from a seropositive donor. Positive serological results during the regular post-transplantation monitoring complemented with or without clinical data are indicative and require further QRT-PCR analysis.

Keywords: CMV, kidney transplant recipient (KTR), seroepidemiologic screening, ELISA, QRT-PCR studies,

pdf - Download FULL TEXT /PDF 558 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Stoykova Z, Ivanova L, Ikonomov V, Teodorova I, Todorova T. Monitoring of CMV infection in kidney transplant recipients. J of IMAB. 2017 Oct-Dec;23(4):1834-1838. DOI: 10.5272/jimab.2017234.1834

Corresponding AutorCorrespondence to: Zhivka Stoykova, Department of Microbiology and Virology, Medical Faculty, Medical University of Varna, 55 Marin Drinov Str., 9002 Varna, Bulgaria; Laboratory of Clinical Virology, University Hospital ‘’St. Marina’’, 1 Hristo Smirnenski Str., 9010 Varna, Bulgaria; E-mail: jivita77@abv.bg

1. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm and puzzle. J Clin Invest. 2011 May;121(5):1673-80. [PubMed] [CrossRef]
2. Mocarski ES, Shenk T, Pass RF. Cytomegalovirus. In: Fields Virology, Knipe DM, Howley PM (Eds). Lippincott Williams and Wilkins, PA, USA. 2007;5: 2701-2772.
3. Humar A, Snydman D, Practice ASTID Co. Cytomegalovirus in solid organ transplant recipients. Am J Transplant.  2009 Dec;9(Suppl 4):S78-86. [PubMed] [CrossRef]
4. Sinclair J. Human cytomegalovirus: Latency and reactivation in the myeloid lineage J Clin Virol.  2008 Mar;41(3):180-5. [PubMed] [CrossRef]
5. Giakoustidis D, Antoniadis A, Fouzas I, Sklavos A, Giakoustidis A, Ouzounidis N, et al. Prevalence and clinical impact of cytomegalovirus infection and disease in renal transplantation: ten years of experience in a single center. Transplant Proc. 2012 Nov;44(9):2715-7. [PubMed] [CrossRef]
6. Ramanan P, Razonable RR. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother. 2013 Sep;45(3):260-71. [PubMed] [CrossRef]
7. Rubin RH. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the 'silo hypothesis'. Curr Opin Infect Dis. 2007 Aug;20(4):399-407. [PubMed] [CrossRef]
8. Stoykova Zh, Ivanova L, Todorova T, Kostadinova Ts, Tsaneva-Damyanova D. Seroprevalence of Cytomegalovirus in the North-Eastern Bulgarian Population 2003-2015. Acta Microbiologica Bulgarica. 2016 Sep;32(3):27-32.
9. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002 Apr 15;34(8):1094-7. [PubMed] [CrossRef]
10. Egli A, Binggeli S, Bodaghi S, Dumoulin A, Funk GA, Khanna N, et al. Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant. 2007 Sep;22 Suppl 8:viii72-viii82. [PubMed] [CrossRef]
11. Carstens J, Andersen HK, Spencer E, Madsen M. Cytomegalovirus infection in renal transplant recipients. Transpl Infect Dis. 2006 Dec;8(4):203-12. [PubMed] [CrossRef]
12. Aguado JM, Navarro D, San Juan R, Castуn JJ. Cytomegalovirus infection in solid organ transplantation. Enferm Infecc Microbiol Clin. 2012 Mar;30 Suppl 2:57-62. [PubMed] [CrossRef]
13. Feng S, Yang J, Wang W, Hu X, Liu H, Qian X, et al. Incidence and Risk Factors for Cytomegalovirus Infection in Patients With Kidney Transplantation: A Single-Center Experience. Transplant Proc. 2016 Oct;48(8):2695-9. [PubMed] [CrossRef]
14. Heemann U, Wenzel RR. CMV prophylaxis! What is valid in 2002? Nephrol Dial Transplant. 2002; 7:556-59.
15. Flechner SM, Avery RR, Fisher R, Mastroianni B, Papajcik D, Malley KJ, t al.  Monitoring of CMV infection after Renal transplantation serology, culture, and viral DNA detection by hybrid capture. Transplant Proc. 1999; 37:1255-1257.
16. Prieser W, Brauninger S, Schwerdtfeger R, Ayliffe U, Garson JA, Brink NS et al.  Evaluation of diagnostic methods from the detection of CMV in recipients of allogenic stem cell transplants. J Clin Virol. 2001;20:59-70.

Received: 29 August 2017
Published online: 18 December 2017

back to Online Journal